Categories
Therapeutic Indications:
Treatment of edema of venous origin in the legs and symptoms associated with chronic venous insufficiency such as heavy and painful legs and swelling.
Adjuverende treatment of internal hemorrhoids in the short term.
Qualitative and quantitative composition:
Venoruton Forte 500 mg tablets
One tablet contains 500 mg of D-(?-Hydroxyethyl)-rutosidea (HR).
Venoruton 300 mg capsules
One capsule contains 300 mg of D-(?-hydroxyethyl)-rutosidea (HR).
Venoruton bags 1000 mg powder for oral solution
A bag contains 1000 mg of O-(?-hydroxyethyl)-rutosidea (HR).
For excipients, see List of excipients.
Pharmaceutical form:
Venoruton Forte 500 mg tablets : circular, biconvex, mottled, yellow-greenish tablet for oral use.
Venoruton 300 mg hard capsules: opaque, yellow-white hard gelatin capsule for oral use.
Venoruton bags 1000 mg powder for oral solution : yellow granular powder for oral administration after solution in a glass of water.
Posology and method of administration:
Venoruton is preferably taken with meals.
Venoruton Forte 500 mg tablets, Venoruton mg powder packets 1000.
Venoruton Forte 500 mg tablets, 1000 mg Venoruton bags are mainly intended to attack the treatment of symptoms associated with chronic venous insufficiency (CVI).
Treatment should be continued until symptoms disappear (usually after 6 to 12 weeks to depending on the severity of symptoms).
Venoruton Forte 500 mg: 2 tablets per day.
Venoruton bags 1000 mg: The contents of the bag and stirred to dissolve completely: 1 sachet per day, to dissolve in a glass of water.
Venoruton Treatment with 300 mg then recommended to maintain the obtained results. Onderhoudsposologie This is in most cases 2 capsules Venoruton 300 mg per day.
Venoruton 300 mg capsules: The dosage is usually 3 capsules per day.
Venoruton 300 mg is primarily intended to continue treatment with Venoruton Forte 500 mg or 1000 mg Venoruton bags as attack therapy was started. In this case, maintenance therapy is usually 2 capsules per day.
For maintenance therapy that some patients may be individually adjusted.
This is a drug, no long use without medical advice, keep away from children, read the leaflet carefully. Ask your doctor or pharmacist. In case of side effects, contact your doctor.
Contraindications:
Known allergy the active ingredient or any of the excipients.
Special warnings and precautions for use:
Treatment with flebotrofe materials should not be continued longer than 3 months without symptoms re-evaluate.
Patients with edema in the lower limbs due to diseases of the heart, kidneys or liver may Venoruton not use because the effect of Venoruton in these indications is not proven.
Pregnancy and lactation:
Over 22 different clinical trials were in total 1431 pregnant women treated with HR. The daily dose varied in most of these studies between 600 mg and 1500 mg (with extremes of 300 mg and 3000 mg). The treatment duration in the majority of these studies was 2 to 4 weeks, with a maximum of 5 to 6 months in 2 studies. These studies reported no fetal abnormalities could be due to the ingestion of Venoruton.
Nevertheless, the administration of Venoruton, as for many drugs, not recommended during the first three months of pregnancy.
In Animal studies have found traces HR in the fetal and breast milk. This negligible amounts of HR are not clinically significant.
Side effects:
occasional mild side effects: skin allergies, headaches, flushing and mild gastrointestinal symptoms. They disappear soon after cessation of treatment.
Effects on ability to drive and use machines:
There is no evidence that Venoruton any impact on the ability to drive and use machines.
Overdose:
To date there is no reported case of overdose.
List of excipients:
Venoruton Forte 500 mg tablets : Polyethylene glycol - Magnesium zan for one tablet.
Venoruton 300 mg capsules: Polyethylene glycol - Gelatin - Titanium Dioxide - yellow iron oxide for a capsule.
Venoruton bags 1000 mg powder for oral solution : Mannitol - Saccharin sodium - Orange Flavor zan for a bag.
Interaction with other medicinal products and other forms of interaction:
No interactions with drugs described.
Has been shown that there are no interactions with the warfarin-type anticoagulants. The components of the active ingredient are derivatives of rutin and quercetin. Itself inhibits an enzyme specific rutin, quercetin inhibits the liver enzyme CYP3A in humans and sulfotransferases in vitro, but not in vivo.
Is therefore assumed that oral-O? (Hydroxyethyl)-rutosides either inhibition or interference in the metabolism of other pharmacologically active substances.
Incompatibilities:
Not applicable.
Follow us